Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

763
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
763
Antigen Processing Pathways01:31

Antigen Processing Pathways

1.5K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
1.5K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

76.0K
Overview
76.0K
Autoimmune Disorders01:29

Autoimmune Disorders

891
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
891
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

302
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
302

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Astrocytic lipid dysregulation as an early driver of neurodegeneration.

Nature reviews. Neurology·2026
Same author

CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy.

Brain pathology (Zurich, Switzerland)·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

Ultra-rare variants in LAMA2 are risk factors for frontotemporal dementia and motor neuron disease.

Human molecular genetics·2026
Same author

Location and mapping of the human rostromedial tegmental nucleus and associated midbrain inhibitory nuclei regulating dopamine neurons.

Brain structure & function·2026
Same author

Systemic dysregulation of apolipoproteins in amyotrophic lateral sclerosis serum.

FEBS open bio·2026

Related Experiment Video

Updated: Oct 19, 2025

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.9K

Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease.

Fiona Bright1, Jared S Katzeff1,2, John R Hodges1,2

  • 1School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.

Frontiers in Immunology
|September 20, 2021
PubMed
Summary

This study explored adaptive immunity in behavioral variant frontotemporal dementia (bvFTD). Researchers identified specific blood serum proteins altered in bvFTD patients with autoimmune disease, suggesting the glycome may be a target.

Keywords:
autoimmune diseasebiomarkerfrontotemporal dementiaglycomeglycoproteinproteomicsserumthyroid

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Related Experiment Videos

Last Updated: Oct 19, 2025

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.9K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Area of Science:

  • Neuroscience
  • Immunology
  • Proteomics

Background:

  • Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder characterized by frontal and temporal lobe involvement.
  • While innate immunity in bvFTD is studied, the role of adaptive immunity remains unclear.
  • Understanding immune system involvement is crucial for unraveling bvFTD pathogenesis.

Purpose of the Study:

  • To investigate the involvement of adaptive immunity in bvFTD.
  • To identify serum proteomic differences associated with autoimmune disease in bvFTD patients.
  • To explore potential glycomic targets in bvFTD with autoimmune disease.

Main Methods:

  • Serum proteomics analysis was performed on bvFTD patients.
  • Patients were categorized based on the presence or absence of autoimmune disease.
  • Statistical analysis identified significantly altered proteins between groups.

Main Results:

  • Eleven proteins showed significant alterations in bvFTD with autoimmune disease compared to those without.
  • Increased proteins included ATP5B, CALML5, COLEC11, FCGBP, PLEK, and PLXND1.
  • Decreased proteins included APOB, ATP8B1, FAM20C, LOXL3, and TIMD4.

Conclusions:

  • Adaptive immunity, specifically involving altered serum proteins, plays a role in bvFTD pathogenesis.
  • The glycome appears to be a targeted component in bvFTD associated with autoimmune disease.
  • These findings open new avenues for understanding bvFTD and developing targeted therapies.